From the New York Vet Show exhibit hall: 3 products addressing veterinary care needs

A once-weekly tablet for cats with early heart disease, a less messy alternative to activated charcoal, and an endoscopy system portable enough for field work were among the products on display last week at 2026 New York Vet Show, held at the Jacob K. Javits Convention Center in New York City. Representatives from the companies behind them spoke with dvm360 on the show floor.

A charcoal alternative designed for less mess

Mat Glassman, VMD, DACVS, MBA, founder and CEO of ReadyRESCUE, told dvm360 at the show that the activated carbon product, made for dogs and cats that have swallowed toxins, is designed as a cleaner, more compact version of activated charcoal. It takes up less volume than traditional charcoal, he said, and doesn’t end up “all over your technicians or your animals.” He said it lasts 5 years on the shelf, compared with 2 years for traditional charcoal, and costs about the same.

ReadyRESCUE is made of synthetic carbon spheres that the company’s website describes as denser and more uniform than powdered charcoal, and it contains no sorbitol.¹ It comes in 30-g vials dosed by body weight and is sold to veterinary practices and directly to pet owners, who can give it at home as a bridge to veterinary care.¹

Glassman said the University of Georgia ran the company’s validation studies by weight.

“It’s just as absorbent as activated charcoal, but our activated carbon just is in a much better delivery format,” he said.

ReadyRESCUE’s website says testing with common toxins found the product as effective by weight as activated charcoal and Toxiban, which it describes as the activated charcoal most commonly used in hospitals.¹

ReadyRESCUE does not work on every toxin. The company’s website says it binds poorly to xylitol, ethylene glycol, alcohols, heavy metals, and corrosive substances, and that it should not be given to animals that are unconscious or that have a gastrointestinal obstruction or a compromised airway. The site also says the product is classified as a device, which the FDA does not formally regulate.¹

The product’s development was guided by veterinary advisers, including Benjamin Brainard, VMD, DACVAA, DACVECC, director of clinical research at the University of Georgia College of Veterinary Medicine.¹

The first conditionally approved drug for feline HCM

Hypertrophic cardiomyopathy (HCM), a thickening of the heart muscle, affects about 1 in 7 pet cats and about 1 in 3 cats older than 9 years. Some cats show no signs of illness for years.²

Felycin-CA1 (sirolimus delayed-release tablets; PRN Pharmacal) became the first drug conditionally approved for cats with HCM when the FDA granted it conditional approval in March 2025 for the management of ventricular hypertrophy in cats with subclinical HCM.² Developed by TriviumVet, the once-weekly tablet launched under the PRN Pharmacal brand in June 2025 and is available only by prescription.^2,3

Dan Fortuna of PRN Pharmacal told dvm360 the company is targeting cats with subclinical HCM in stages B1 and B2, particularly those at higher risk of the disease, including certain purebred cats and older males. Finding those cats, he said, means bringing more of them in for blood work, including NT-proBNP testing.

“I feel personally it’s going to revolutionize how we deal with cats on a wellness basis,” Fortuna said.

Sirolimus is used at higher doses in people to prevent organ transplant rejection. In its approval announcement, the FDA said the drug is not expected to suppress the immune system at the dose given to cats. The agency said cats should be screened for liver disease before starting the drug and that it should not be used in cats with preexisting liver disease or diabetes mellitus.²

The FDA grants conditional approval to drugs that treat a serious or life-threatening disease or meet an unmet animal health need when proving their effectiveness would require a particularly difficult study. Detecting subclinical HCM requires advanced diagnostics, the agency noted, which makes it hard to enroll enough cats in a trial.²

The approval followed the RAPACAT trial, a randomized, double-blinded, placebo-controlled study of 43 client-owned cats with subclinical HCM at 2 veterinary referral centers. The cats received a placebo or a low or high dose of delayed-release rapamycin—another name for sirolimus—once a week for 6 months. At the end of the study, maximum left ventricular wall thickness was significantly lower in the low-dose group than in the placebo group. The drug was well tolerated, with no significant difference in adverse events between groups.⁴ That low dose, 0.3 mg/kg, is the approved target dose for Felycin-CA1.^2,4

A larger trial, the HALT HCM Study, is meant to support full approval. The blinded, randomized, placebo-controlled study, run by TriviumVet at clinical sites across the United States, follows cats with American College of Veterinary Internal Medicine (ACVIM) stage B1 or B2 HCM and elevated NT-proBNP concentrations through 12 months of once-weekly dosing.⁵ TriviumVet lists the study as fully enrolled.⁶ In March 2025, the company said it aimed to enroll 300 cats and expected to complete the study by 2028.⁷

An endoscopy system built to travel

The All in One Endoscopy System from Panther Veterinary, a division of Panther Healthcare, combines an HD camera, image processor, and light source in a single console that runs both flexible and rigid scopes. According to the product page on Panther’s website, the system handles flexible procedures such as upper gastrointestinal endoscopy and bronchoscopy as well as rigid procedures such as laparoscopy and arthroscopy, with scopes and accessories sized for companion, large, and exotic animals.⁸

A Panther Healthcare representative told dvm360 the system is compact and portable enough for field work with horses and other large animals. It includes a 3-meter scope for equine use and suction, air, and water attachments, the representative said, and it can connect to a larger monitor.

“The light source is built into the system, so it’s very easy to use and very easy to set up,” the representative said.

Up next: Fetch Long Beach

The Fetch Long Beach Veterinary Conference runs Dec. 3–5, 2026, in Long Beach, California. dvm360 will share a look at products from its exhibit hall after the show.

References

1. ReadyRESCUE: lifesaving tool for chocolate & other pet poisons. ReadyRESCUE. Accessed November 6, 2026. https://drcuddles.com/products/readyrescue
2. McCafferty C. FDA conditionally approves first drug for feline subclinical hypertrophic cardiomyopathy. dvm360. March 14, 2025. Accessed November 6, 2026. https://www.dvm360.com/view/fda-conditionally-approves-first-drug-for-feline-subclinical-hypertrophic-cardiomyopathy
3. Crossley KC. Novel cardiology therapy for cats is launched. dvm360. June 18, 2025. Accessed November 6, 2026. https://www.dvm360.com/view/novel-cardiology-therapy-for-cats-is-launched
4. Kaplan JL, Rivas VN, Walker AL, et al. Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial. J Am Vet Med Assoc. 2023;261(11):1628-1637. doi:10.2460/javma.23.04.0187
5. The HALT study: study summary. TriviumVet. Accessed November 6, 2026. https://assets.ctfassets.net/rt5zmd3ipxai/6jSR6nqPwruk8Cl9rl1AbJ/10420b160dfd2b067e89d78b74999045/HALT_HCM_STUDY.pdf
6. Clinical studies. TriviumVet. Accessed November 6, 2026. https://www.triviumvet.com/clinical-studies
7. TriviumVet secures FDA conditional approval for feline cardiology disease. News release. TriviumVet. March 14, 2025. Accessed November 6, 2026. https://www.triviumvet.com/blog/triviumvet-secures-fda-conditional-approval-for-feline-cardiology-disease
8. Panther All in One Endoscopy System. Panther Veterinary. Accessed November 6, 2026. https://www.pantherus.vet/products/panther-endoscopy-system